GLP-1 receptor agonists are effective treatments for obesity but are less accessible worldwide than pharmacological treatments for diabetes, reflecting biases and lack of education, and perpetuating health inequalities.
References
Michaelidou, M., Pappachan, J. M. & Jeeyavudeen, M. S. World J. Diabetes 14, 396–411 (2023).
Gomez, G. & Stanford, F. C. Int. J. Obes. 42, 495–500 (2018).
Bessesen, D. H. & Van Gaal, L. F. Lancet Diabetes Endocrinol. 6, 237–248 (2018).
Washington, T. B. et al. Gastroenterol Clin North Am 52, 429–441 (2023).
Nauck, M. A. & Meier, J. J. Diabetes Obes. Metab. 20, 5–21 (2018).
Drucker, D. J. Mol. Metab. 57, 101351 (2022).
Chatterjee, S., Khunti, K. & Davies, M. J. Lancet 389, 2239–2251 (2017).
ElSayed, N. A. et al. Diabetes Care 46(Suppl. 1), S5–S9 (2022).
Grunvald, E. et al. Gastroenterology 163, 1198–1225 (2022).
Uerlich, M. F., Yumuk, V., Finer, N., Basdevant, A. & Visscher, T. L. Obes. Facts 9, 273–283 (2016).
Meikle, A. et al. Semaglutide for managing overweight and obesity: technology appraisal guidance (UK NICE, 2023).
Cohen, J. Forbes (11 June 2023).
Kyle, T. K. & Stanford, F. C. Obesity 24, 1832 (2016).
Jannah, N., Hild, J., Gallagher, C. & Dietz, W. Obesity 26, 1834–1840 (2018).
Sumarsono, A. et al. Diabetes Care 43, 2684–2690 (2020).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Rights and permissions
About this article
Cite this article
Waldrop, S.W., Johnson, V.R. & Stanford, F.C. Inequalities in the provision of GLP-1 receptor agonists for the treatment of obesity. Nat Med 30, 22–25 (2024). https://doi.org/10.1038/s41591-023-02669-x
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41591-023-02669-x
- Springer Nature America, Inc.